Get started
NOVAVAX INCNOVAVAX INCNOVAVAX INC

NOVAVAX INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NVAX trade ideas

NVAX to attack down trend line again, Watch carefully !NVAX is going to attack the down trend line once more after a short recovery and regaining some energy. Who wins the battle? lets follow and see. NVAX has reacted well to very strong support formed by 0.618 Retracement of last major rally and 0.786 projection of possible wave A of an ABC form of correction. This is shown on the chart. It is worth to note that chart is in logarithmic scale. I, myself think that NVAX is not able to break the line this time and it needs one more attack later. But who knows? Please take into consideration that : Market never follows our predictions , We are the one who should follow the market. Good luck my friends
NASDAQ:NVAX
by SaeedSajedi
5
Are we close to observe a breakout on NVAX ?Novavax COVID-19 vaccine more than 90% effective in U.S trial according to Reuters. Despite positive news (which we do not trade), we will share with you our current view on Novavax. a) The price is inside a descending Wedge, and due to positive news, we are observing a bullish GAP, and we may see the price outside the Wedge pattern b) The general strategy we will use to develop bullish setups on the pharmaceutical company is waiting for the price to reach 250 - 270 and then an ABC corrective pattern, as you can see on the chart. c) IF that scenario happens, we will trade above B, and our stop loss will be set below C d) Regarding the targets, we will be using the Fibo Extensions of the major descending wedge Thanks for reading!
NASDAQ:NVAXLong
by ThinkingAntsOk
5
$NVAX Leaps Calls 480 Jan 21st 2022 or Commons A different kind of COVID-19 vaccine is coming, and it could be 'even more protective' A COVID-19 vaccine different from those made by Moderna, Johnson & Johnson, and Pfizer could be available to Americans "as soon as this summer," NPR reported on Sunday. The three vaccines currently authorized for use in the U.S. work by instructing the body to manufacture something that looks like a piece of the virus, but isn't. Then, if ever infected with the real virus, the immune system is prepared. The new protein subunit vaccine, however, already contains that all-important bit, known as the spike protein, meaning the body doesn't have to produce it on its own. What's more, the protein subunit vaccine doesn't require "special refrigeration," and also contains an "adjuvant" that makes the shot "even more protective," per NPR. The technology itself isn't novel — there are hepatitis B and pertussis vaccines that use the same science. But the first COVID-19 iteration will likely come from biotech company Novavax, which is reportedly hoping to file for authorization in "the U.K., U.S., and Europe in the third quarter," said NPR. Canadian biotech firm Medicago and pharmaceutical giant Sanofi are working to create their own versions, as well. Read more at NPR.
NASDAQ:NVAXLong
by UnknownUnicorn19246015
1